Buy Or Sell Opportunity • Mar 11
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 20% to ₩15,370. The fair value is estimated to be ₩12,643, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩14,860, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 51% over the past three years. 공시 • Mar 05
Kangnam Jevisco Co., Ltd, Annual General Meeting, Mar 26, 2026 Kangnam Jevisco Co., Ltd, Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 639, jungang-daero, busanjin-gu, busan South Korea 공시 • Feb 13
Kangnam Jevisco Co., Ltd announces Annual dividend Kangnam Jevisco Co. Ltd. announced Annual dividend of KRW 250.0000 per share, ex-date on February 26, 2026 and record date on February 27, 2026. Buy Or Sell Opportunity • Jan 08
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 25% to ₩14,970. The fair value is estimated to be ₩12,063, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.5% over the last 3 years. Meanwhile, the company has become profitable. New Risk • May 23
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.5% Last year net profit margin: 3.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.5% net profit margin). Board Change • Apr 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Chairperson Ye-Jung Lim was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Mar 31
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩146.6b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩146.6b market cap, or US$99.5m). Reported Earnings • Mar 22
Full year 2024 earnings released: EPS: ₩2,039 (vs ₩2,541 in FY 2023) Full year 2024 results: EPS: ₩2,039 (down from ₩2,541 in FY 2023). Revenue: ₩643.1b (flat on FY 2023). Net income: ₩13.3b (down 20% from FY 2023). Profit margin: 2.1% (down from 2.6% in FY 2023). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩26,700, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 25% over the past three years. Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩29.00 (vs ₩211 in 3Q 2023) Third quarter 2024 results: EPS: ₩29.00 (down from ₩211 in 3Q 2023). Revenue: ₩153.6b (down 3.3% from 3Q 2023). Net income: ₩188.8m (down 86% from 3Q 2023). Profit margin: 0.1% (down from 0.9% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Dec 20
Upcoming dividend of ₩500 per share at 2.4% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.8%). New Risk • Oct 10
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩131.6b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (92% cash payout ratio). Large one-off items impacting financial results. Market cap is less than US$100m (₩131.6b market cap, or US$97.8m). New Risk • Aug 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.9b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 128% Paying a dividend despite having no free cash flows. Earnings have declined by 15% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩132.9b market cap, or US$99.3m). Reported Earnings • May 20
First quarter 2023 earnings released: ₩75.00 loss per share (vs ₩487 profit in 1Q 2022) First quarter 2023 results: ₩75.00 loss per share (down from ₩487 profit in 1Q 2022). Revenue: ₩149.4b (down 8.9% from 1Q 2022). Net loss: ₩486.2m (down 115% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩23,700, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 45% over the past three years. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩26,150, the stock trades at a trailing P/E ratio of 27.5x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 77% over the past three years. Reported Earnings • Mar 24
Full year 2022 earnings released: EPS: ₩952 (vs ₩6,948 in FY 2021) Full year 2022 results: EPS: ₩952 (down from ₩6,948 in FY 2021). Revenue: ₩673.2b (up 14% from FY 2021). Net income: ₩6.19b (down 86% from FY 2021). Profit margin: 0.9% (down from 7.6% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Upcoming Dividend • Dec 21
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 28 April 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (2.4%). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Chairperson Ye-Jung Lim was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Chairperson Ye-Jung Lim was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. Payout ratio is a comfortable 3.6% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (1.5%). Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improved over the past week After last week's 23% share price gain to ₩30,350, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 20x in the Chemicals industry in South Korea. Negligible returns to shareholders over past three years. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS ₩3,583 (vs ₩2,250 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩340.8b (up 2.5% from FY 2019). Net income: ₩23.3b (up 59% from FY 2019). Profit margin: 6.8% (up from 4.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. 공시 • Mar 05
Kangnam Jevisco Co., Ltd, Annual General Meeting, Mar 25, 2021 Kangnam Jevisco Co., Ltd, Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Mar 02
New 90-day high: ₩23,100 The company is up 23% from its price of ₩18,800 on 02 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 21
New 90-day high: ₩23,000 The company is up 43% from its price of ₩16,050 on 23 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 39% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩500 Per Share Will be paid on the 24th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.4% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.9%). Is New 90 Day High Low • Dec 09
New 90-day high: ₩19,100 The company is up 19% from its price of ₩16,050 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. Is New 90 Day High Low • Nov 06
New 90-day high: ₩17,100 The company is up 13% from its price of ₩15,200 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.